发明授权
US08420321B2 Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism
失效
通过确定TAFI-Ile347多态性来鉴定血栓形成障碍风险的方法
- 专利标题： Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism
- 专利标题（中）： 通过确定TAFI-Ile347多态性来鉴定血栓形成障碍风险的方法
-
申请号： US13109111申请日： 2011-05-17
-
公开(公告)号： US08420321B2公开(公告)日： 2013-04-16
- 发明人: Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
- 申请人： Detlef Kozian , Stefan Schaefer , Bernward Schoelkens , Karl-Ernst Siegler , Jean-Francois Deleuze , Sylvain Ricard , Sandrine Mace
- 申请人地址： DE Frankfurt am Main
- 专利权人： Sanofi-Aventis Deutschland GmbH
- 当前专利权人： Sanofi-Aventis Deutschland GmbH
- 当前专利权人地址： DE Frankfurt am Main
- 优先权： EP03026030 20031112
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68 ; G01N33/48 ; G01N33/68 ; C12P13/08 ; C12P13/06
摘要：
The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
公开/授权文献
信息查询
